Biotech Values

[DewDiligence]

There’s ordinary K-M censoring—what you just described—but there’s another kind of censoring, informally speaking. We’ve all seen data presentations that exclude troublesome data points based on some post hoc criterion, and such cherry-picking may be described to an investor audience as a form of censoring.